Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Selective norepinephrine reuptake inhibitors, particularly atomoxetine, reboxetine and 2-alkylthio substituted phenoxyphenyl propylamines, are used for the treatment of cognitive failure, including cognitive failure due to dementia, delirium and schizophrenia.

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: GEHLERT DONALD RICHARD,BYMASTER FRANKLIN PORTER,MCKINZIE DAVID LEE,YANG CHARLES RENKIN
Format: Patent
Sprache:eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator GEHLERT DONALD RICHARD,BYMASTER FRANKLIN PORTER,MCKINZIE DAVID LEE,YANG CHARLES RENKIN
description Selective norepinephrine reuptake inhibitors, particularly atomoxetine, reboxetine and 2-alkylthio substituted phenoxyphenyl propylamines, are used for the treatment of cognitive failure, including cognitive failure due to dementia, delirium and schizophrenia.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN1713900A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN1713900A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN1713900A3</originalsourceid><addsrcrecordid>eNqFi7EKwkAQBa-xEPUb3B8QElKIpQTFSiy0Dmd45y2Je8fexu9Xwd5mppmZu8utgFIgSYrMghz1Q1JM2fwAYol8Z0taKCQliyBTeHtC7Pv16SFs_AIFz-OkWLpZ8GPB6ueFWx8P1_a0QU4dSvY9BNa153pbN7uq2jf_izcD1zcC</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure</title><source>esp@cenet</source><creator>GEHLERT DONALD RICHARD,BYMASTER FRANKLIN PORTER,MCKINZIE DAVID LEE,YANG CHARLES RENKIN</creator><creatorcontrib>GEHLERT DONALD RICHARD,BYMASTER FRANKLIN PORTER,MCKINZIE DAVID LEE,YANG CHARLES RENKIN</creatorcontrib><description>Selective norepinephrine reuptake inhibitors, particularly atomoxetine, reboxetine and 2-alkylthio substituted phenoxyphenyl propylamines, are used for the treatment of cognitive failure, including cognitive failure due to dementia, delirium and schizophrenia.</description><edition>7</edition><language>eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2005</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20051228&amp;DB=EPODOC&amp;CC=CN&amp;NR=1713900A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20051228&amp;DB=EPODOC&amp;CC=CN&amp;NR=1713900A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GEHLERT DONALD RICHARD,BYMASTER FRANKLIN PORTER,MCKINZIE DAVID LEE,YANG CHARLES RENKIN</creatorcontrib><title>Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure</title><description>Selective norepinephrine reuptake inhibitors, particularly atomoxetine, reboxetine and 2-alkylthio substituted phenoxyphenyl propylamines, are used for the treatment of cognitive failure, including cognitive failure due to dementia, delirium and schizophrenia.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2005</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFi7EKwkAQBa-xEPUb3B8QElKIpQTFSiy0Dmd45y2Je8fexu9Xwd5mppmZu8utgFIgSYrMghz1Q1JM2fwAYol8Z0taKCQliyBTeHtC7Pv16SFs_AIFz-OkWLpZ8GPB6ueFWx8P1_a0QU4dSvY9BNa153pbN7uq2jf_izcD1zcC</recordid><startdate>20051228</startdate><enddate>20051228</enddate><creator>GEHLERT DONALD RICHARD,BYMASTER FRANKLIN PORTER,MCKINZIE DAVID LEE,YANG CHARLES RENKIN</creator><scope>EVB</scope></search><sort><creationdate>20051228</creationdate><title>Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure</title><author>GEHLERT DONALD RICHARD,BYMASTER FRANKLIN PORTER,MCKINZIE DAVID LEE,YANG CHARLES RENKIN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN1713900A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2005</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>GEHLERT DONALD RICHARD,BYMASTER FRANKLIN PORTER,MCKINZIE DAVID LEE,YANG CHARLES RENKIN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GEHLERT DONALD RICHARD,BYMASTER FRANKLIN PORTER,MCKINZIE DAVID LEE,YANG CHARLES RENKIN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure</title><date>2005-12-28</date><risdate>2005</risdate><abstract>Selective norepinephrine reuptake inhibitors, particularly atomoxetine, reboxetine and 2-alkylthio substituted phenoxyphenyl propylamines, are used for the treatment of cognitive failure, including cognitive failure due to dementia, delirium and schizophrenia.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_CN1713900A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T22%3A26%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GEHLERT%20DONALD%20RICHARD,BYMASTER%20FRANKLIN%20PORTER,MCKINZIE%20DAVID%20LEE,YANG%20CHARLES%20RENKIN&rft.date=2005-12-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN1713900A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true